Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, SickKids Hospital, University of Toronto, Toronto, Ontario, Canada.
Group for Improvement of Intestinal Function and Treatment (GIFT), SickKids Hospital, Toronto, Ontario, Canada.
JPEN J Parenter Enteral Nutr. 2021 Sep;45(7):1432-1440. doi: 10.1002/jpen.2055. Epub 2021 Jan 7.
Catheter-related thrombosis (CRT) is a devastating complication of central venous catheters in children with intestinal failure (IF), but the optimal preventive therapy of CRT is unknown. This study assessed the efficacy and safety of 2 protocols of secondary anticoagulation prophylaxis with low-molecular-weight heparin (LMWH).
This is a comparative cohort study of children from 2 IF programs who received secondary anticoagulation prophylaxis with LMWH for CRT. The short-term protocol group (N = 13) received therapeutic dosing until thrombus resolution or ≤3 months. In the long-term protocol group (N = 26), prophylactic dosing continued until line removal. Patients underwent routine annual vascular ultrasound and were followed for ≥1 year. The primary outcome was development of secondary thrombosis; post hoc analysis assessed rates of secondary thrombosis at 12 months.
Patient demographics were similar between groups. Secondary thrombosis occurred in 8 of 13 (62%) patients in the short-term group and in 9 of 26 (35%) in the long-term protocol group (P = .019) in a median time of 144.5 and 689 days, respectively (P = .01). Secondary thrombosis within 12 months occurred in 7 of 13 (54%, short term) and 2 of 26 (8%, long term) patients (P = .001). Secondary thrombosis was associated with catheter replacements (23.5 vs 5.5 catheters per 1000 catheter days; P = .016) and longer daily parenteral nutrition (PN) infusion (24 vs 15.25 hours; P = .044). Compliance was good (>80% of doses) in 92% of patients.
Long-term secondary anticoagulation prophylaxis with LMWH reduces the incidence of secondary thrombosis and should be considered in children with CRT that require PN for prolonged periods of time.
在患有肠衰竭(IF)的儿童中,导管相关性血栓形成(CRT)是中心静脉导管的一种破坏性并发症,但 CRT 的最佳预防治疗方法尚不清楚。本研究评估了两种低分子肝素(LMWH)二级抗凝预防方案的疗效和安全性。
这是一项比较性队列研究,纳入了来自 2 个 IF 项目的接受 LMWH 二级抗凝预防 CRT 的儿童。短期方案组(N=13)接受治疗剂量,直至血栓溶解或≤3 个月。在长期方案组(N=26)中,预防性剂量一直持续到导管移除。患者接受常规年度血管超声检查,并随访至少 1 年。主要结局是发生继发性血栓形成;事后分析评估了 12 个月时继发性血栓形成的发生率。
两组患者的人口统计学特征相似。短期组 13 例患者中有 8 例(62%)发生继发性血栓形成,长期组 26 例患者中有 9 例(35%)发生继发性血栓形成(P=0.019),中位时间分别为 144.5 天和 689 天(P=0.01)。在 12 个月内,短期组 13 例患者中有 7 例(54%)和长期组 26 例患者中有 2 例(8%)发生继发性血栓形成(P=0.001)。继发性血栓形成与导管更换(每 1000 个导管日更换 23.5 个与 5.5 个导管;P=0.016)和更长的每日肠外营养(PN)输注时间(24 小时与 15.25 小时;P=0.044)相关。92%的患者依从性良好(>80%的剂量)。
长期使用 LMWH 进行二级抗凝预防可降低继发性血栓形成的发生率,对于需要长时间 PN 的 CRT 儿童应考虑使用。